Annette Schaub1, Kim T Mueser2, Thomas von Werder3, Rolf Engel3, Hans-Jürgen Möller3, Peter Falkai3. 1. Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Munich, Germany; annette.schaub@med.uni-muenchen.de. 2. Center for Psychiatric Rehabilitation, Boston University, Boston, MA. 3. Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Munich, Germany;
Abstract
OBJECTIVE: Over the past 30 years, illness management programs and cognitive-behavioral therapy for psychosis have gained prominence in the treatment of schizophrenia. However, little is known about the long-term benefits of these types of programs when delivered during inpatient treatment following a symptom exacerbation. To evaluate this question, we conducted a randomized controlled trial comparing the long-term effects of a group-based coping-oriented program (COP) that combined the elements of illness management with cognitive behavioral-therapy for psychosis, with an equally intensive supportive therapy (SUP) program. METHOD:196 inpatients with DSM-IV schizophrenia were randomized to COP or SUP, each lasting 12 sessions provided over 6-8 weeks. Outcome measures were collected in the hospital at baseline and post-assessment, and following discharge into the community 1 and 2 years later. We compared the groups on rehospitalizations, symptoms, psychosocial functioning, and knowledge about psychosis. RESULTS: Intent-to-treat analyses indicated that patients in COP learned significantly more information about psychosis, and had greater reductions in overall symptoms and depression/anxiety over the treatment and follow-up period than patients in SUP. Patients in both groups improved significantly in other symptoms and psychosocial functioning. There were no differences between the groups in hospitalization rates, which were low. CONCLUSIONS:People with schizophrenia can benefit from short-term COPs delivered during the inpatient phase, with improvements sustaining for 2 years following discharge from the hospital. More research is needed to evaluate the long-term impact of coping-oriented and similar programs provided during inpatient treatment.
RCT Entities:
OBJECTIVE: Over the past 30 years, illness management programs and cognitive-behavioral therapy for psychosis have gained prominence in the treatment of schizophrenia. However, little is known about the long-term benefits of these types of programs when delivered during inpatient treatment following a symptom exacerbation. To evaluate this question, we conducted a randomized controlled trial comparing the long-term effects of a group-based coping-oriented program (COP) that combined the elements of illness management with cognitive behavioral-therapy for psychosis, with an equally intensive supportive therapy (SUP) program. METHOD: 196 inpatients with DSM-IV schizophrenia were randomized to COP or SUP, each lasting 12 sessions provided over 6-8 weeks. Outcome measures were collected in the hospital at baseline and post-assessment, and following discharge into the community 1 and 2 years later. We compared the groups on rehospitalizations, symptoms, psychosocial functioning, and knowledge about psychosis. RESULTS: Intent-to-treat analyses indicated that patients in COP learned significantly more information about psychosis, and had greater reductions in overall symptoms and depression/anxiety over the treatment and follow-up period than patients in SUP. Patients in both groups improved significantly in other symptoms and psychosocial functioning. There were no differences between the groups in hospitalization rates, which were low. CONCLUSIONS:People with schizophrenia can benefit from short-term COPs delivered during the inpatient phase, with improvements sustaining for 2 years following discharge from the hospital. More research is needed to evaluate the long-term impact of coping-oriented and similar programs provided during inpatient treatment.
Authors: Dawn Velligan; Thomas Prihoda; Ellen Dennehy; Melanie Biggs; Kathy Shores-Wilson; M Lynn Crismon; A John Rush; Alexander Miller; Trisha Suppes; Madhukar Trivedi; T Michael Kashner; Bradley Witte; Marcia Toprac; Thomas Carmody; John Chiles; Stephen Shon Journal: Psychiatry Res Date: 2005-06-30 Impact factor: 3.222
Authors: Alan B McGuire; Marina Kukla; Amethyst Green; Daniel Gilbride; Kim T Mueser; Michelle P Salyers Journal: Psychiatr Serv Date: 2014-02-01 Impact factor: 3.084
Authors: Bert-Jan Roosenschoon; Jaap van Weeghel; Mathijs L Deen; Emmie W van Esveld; Astrid M Kamperman; Cornelis L Mulder Journal: Front Psychiatry Date: 2021-12-14 Impact factor: 4.157